Bell, Mark, Foley, David ![]() |
Preview |
PDF
- Published Version
Available under License Creative Commons Attribution. Download (440kB) | Preview |
Official URL: http://dx.doi.org/10.1016/j.bmcl.2018.07.044
Abstract
The oral S1PR1 agonist ponesimod demonstrated substantial efficacy in a phase II clinical trial of psoriasis. Unfortunately, systemic side effects were observed, which included lymphopenia and transient bradycardia. We sought to develop a topical soft-drug S1PR1 agonist with an improved therapeutic index. By modifying ponesimod, we discovered an ester series of S1PR agonists. To increase metabolic instability in plasma we synthesised esters described as specific substrates for paraoxonase and butyrylcholinesterases, esterases present in human plasma.
Item Type: | Article |
---|---|
Date Type: | Publication |
Status: | Published |
Schools: | Biosciences |
Publisher: | Elsevier |
ISSN: | 0960-894X |
Date of First Compliant Deposit: | 31 July 2018 |
Date of Acceptance: | 29 July 2018 |
Last Modified: | 23 May 2023 17:51 |
URI: | https://orca.cardiff.ac.uk/id/eprint/113787 |
Citation Data
Cited 14 times in Scopus. View in Scopus. Powered By Scopus® Data
Actions (repository staff only)
![]() |
Edit Item |